The European Commission approves the use of XADAGO® as add-on to L-dopa alone or in combination with other PD medications in mid-late stage PD patients with motor fluctuations
February 5, 2015 – Milan, Italy – Newron Pharmaceuticals S.p.A. (“Newron”) [Ticker: SIX: NWRN], a research and development company focused on novel central nervous system (CNS)
Milan, Italy, January 15, 2015 – Newron Pharmaceuticals S.p.A. (“Newron”), a research and development company focused on novel CNS and pain therapies, announced today the
Milan, Italy, January 15, 2015 – Newron Pharmaceuticals S.p.A. (“Newron”), a research and development company focused on novel CNS and pain therapies, announced today the
Milan, Italy, January 14, 2015 – Newron Pharmaceuticals S.p.A. (“Newron”), a research and development company focused on novel CNS and pain therapies, announced today the
The information on the following pages may be made available in the United States. By clicking on the link below, you agree that you are in the United States.
